It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Drugs of abuse represent a growing public health crisis. Accumulating evidence indicates that gabapentin (GBP), a prescription drug, is prone to misuse, abuse, withdrawal, and dependence. Commonly, drugs of abuse modulate the dopaminergic system to induce addiction. In this study, we used the conditioned place preference (CPP) model to investigate the involvement of the dopamine 1 (D1) receptor on the reward and reinforcement behavior of GBP. Under a CPP paradigm, male BALB/c mice were intraperitoneally injected either saline or 100, 200, or 300 mg/kg of GBP and confined to the injection-paired chamber for 30 min. In the pre-conditioning phase, mice were conditioned for 3 days, and baseline data were collected. In the conditioning phase, mice were given once-daily alternating injections of either GBP or saline for 8 days and subsequently assessed in a post-conditioning test. Injections of 300 mg/kg of GBP significantly increased the time spent in the drug-paired chamber compared to the saline-paired chamber. However, lower doses of GBP (100 and 200 mg/kg) showed no effect. Pre-treatment with SKF-83566, a D1 receptor antagonist, attenuated GBP-induced CPP. Thus, for the first time, we show that GBP can induce CPP through a dopaminergic-dependent mechanism.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Taif University, Department of Pharmacology and Toxicology, College of Pharmacy, Taif, Saudi Arabia (GRID:grid.412895.3) (ISNI:0000 0004 0419 5255); Taif University, Addiction and Neuroscience Research Unit, Biomedical Sciences Research Center, Taif, Saudi Arabia (GRID:grid.412895.3) (ISNI:0000 0004 0419 5255); Ministry of Interior, General Directorate of Narcotics Control, General Administration for Precursors and Laboratories, Riyadh, Saudi Arabia (GRID:grid.412895.3)
2 Taif University, Addiction and Neuroscience Research Unit, Biomedical Sciences Research Center, Taif, Saudi Arabia (GRID:grid.412895.3) (ISNI:0000 0004 0419 5255)
3 Umm Al-Qura University, Department of Pharmacology and Toxicology, College of Pharmacy, Makkah, Saudi Arabia (GRID:grid.412832.e) (ISNI:0000 0000 9137 6644)
4 Taif University, Addiction and Neuroscience Research Unit, Biomedical Sciences Research Center, Taif, Saudi Arabia (GRID:grid.412895.3) (ISNI:0000 0004 0419 5255); Taif University, Deanship of Scientific Research, Taif, Saudi Arabia (GRID:grid.412895.3) (ISNI:0000 0004 0419 5255)
5 Taif University, Addiction and Neuroscience Research Unit, Biomedical Sciences Research Center, Taif, Saudi Arabia (GRID:grid.412895.3) (ISNI:0000 0004 0419 5255); Taif University, Department of Pharmaceutical Chemistry, College of Pharmacy, Taif, Saudi Arabia (GRID:grid.412895.3) (ISNI:0000 0004 0419 5255)
6 Taif University, Addiction and Neuroscience Research Unit, Biomedical Sciences Research Center, Taif, Saudi Arabia (GRID:grid.412895.3) (ISNI:0000 0004 0419 5255); Taif University, Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, Taif, Saudi Arabia (GRID:grid.412895.3) (ISNI:0000 0004 0419 5255)
7 Taif University, Addiction and Neuroscience Research Unit, Biomedical Sciences Research Center, Taif, Saudi Arabia (GRID:grid.412895.3) (ISNI:0000 0004 0419 5255); Taif University, Department of Clinical Laboratories Science, Faculty of Applied Medical Sciences, Taif, Saudi Arabia (GRID:grid.412895.3) (ISNI:0000 0004 0419 5255)
8 Taif University, Addiction and Neuroscience Research Unit, Biomedical Sciences Research Center, Taif, Saudi Arabia (GRID:grid.412895.3) (ISNI:0000 0004 0419 5255); Taif University, Department of Biology, Faculty of Science, Taif, Saudi Arabia (GRID:grid.412895.3) (ISNI:0000 0004 0419 5255)
9 Ministry of Health, Department of Pharmaceutical Care, Directorate of Health Affairs, Taif, Saudi Arabia (GRID:grid.415696.9)
10 University of Toledo, Department of Physiology and Pharmacology, College of Medicine and Life Sciences, Toledo, USA (GRID:grid.267337.4) (ISNI:0000 0001 2184 944X)
11 University of Toledo, Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, Toledo, USA (GRID:grid.267337.4) (ISNI:0000 0001 2184 944X)